Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Mechanisms of action and therapeutic application of glucagon-like peptide-1

Drucker DJ. Cell Metabolism 2018

Document identifier
CEI-BR-016
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Drucker DJ
Title
Mechanisms of action and therapeutic application of glucagon-like peptide-1
Source
Cell Metabolism
Year
2018
Volume, issue, pages
27(4):740–756
Digital object identifier
10.1016/j.cmet.2018.03.001
PubMed identifier
29617641
Record type
Journal article
Institute identifier
CEI-BR-016

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: SemaglutideCompound monograph
Monograph: LiraglutideCompound monograph
Monograph: DulaglutideCompound monograph
Monograph: ExenatideCompound monograph
Monograph: LixisenatideCompound monograph
Monograph: OrforglipronCompound monograph
Monograph: DanuglipronCompound monograph
Monograph: EcnoglutideCompound monograph
Monograph: TeduglutideCompound monograph
Synthesis: Dulaglutide in type 2 diabetes mellitus: effect on the anchor outcomeEvidence synthesis
Synthesis: Exenatide in type 2 diabetes mellitus: effect on the anchor outcomeEvidence synthesis
Synthesis: Lixisenatide in type 2 diabetes mellitus: effect on the anchor outcomeEvidence synthesis
Synthesis: Orforglipron in type 2 diabetes mellitus: effect on the anchor outcomeEvidence synthesis
Synthesis: Exenatide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Liraglutide in obesity and overweight in adults: effect on the anchor…Evidence synthesis
Synthesis: Orforglipron in obesity and overweight in adults: effect on the…Evidence synthesis
Synthesis: Teduglutide in inflammatory bowel disease and mucosal barrier…Evidence synthesis
Synthesis: Dulaglutide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Liraglutide in adjunctive therapy in type 1 diabetes: effect on the…Evidence synthesis
Synthesis: Liraglutide in type 2 diabetes mellitus: effect on the anchor outcomeEvidence synthesis
Synthesis: Dulaglutide in type 2 diabetes mellitus: tolerability and…Evidence synthesis
Synthesis: Exenatide in type 2 diabetes mellitus: tolerability and…Evidence synthesis
Synthesis: Lixisenatide in type 2 diabetes mellitus: tolerability and…Evidence synthesis
Synthesis: Orforglipron in type 2 diabetes mellitus: tolerability and…Evidence synthesis
Synthesis: Exenatide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Liraglutide in obesity and overweight in adults: tolerability and…Evidence synthesis
Synthesis: Orforglipron in obesity and overweight in adults: tolerability and…Evidence synthesis
Synthesis: Teduglutide in inflammatory bowel disease and mucosal barrier…Evidence synthesis
Synthesis: Dulaglutide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Liraglutide in adjunctive therapy in type 1 diabetes: tolerability…Evidence synthesis
Synthesis: Liraglutide in type 2 diabetes mellitus: tolerability and…Evidence synthesis
Synthesis: Dulaglutide in type 2 diabetes mellitus: durability of effectEvidence synthesis
Synthesis: Exenatide in type 2 diabetes mellitus: durability of effectEvidence synthesis
Synthesis: Lixisenatide in type 2 diabetes mellitus: durability of effectEvidence synthesis
Synthesis: Orforglipron in type 2 diabetes mellitus: durability of effectEvidence synthesis
Synthesis: Exenatide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Liraglutide in obesity and overweight in adults: durability of effectEvidence synthesis
Synthesis: Orforglipron in obesity and overweight in adults: durability of effectEvidence synthesis
Synthesis: Teduglutide in inflammatory bowel disease and mucosal barrier…Evidence synthesis
39 citing documents.

§1.3Subject tags

glp-1 mechanism review

Compound Evidence Institute · CEI-BR-016 · https://compoundevidence.com/bibliography/drucker2018/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.